General Information
Drug ID
DR00106
Drug Name
Tetraethylammonium
Synonyms
4-04-00-00331 (Beilstein Handbook Reference); 56-34-8 (chloride); 5AV7G7EIEE; 66-40-0; 68-05-3 (iodide); 71-91-0 (bromide); 77-98-5 (hydroxide); AC1L1KAW; AMMONIUM, TETRAETHYL-; BRN 1738225; C8H20N; CHEBI:44296; CHEMBL9324; Ethanaminium; GTPL2343; GTPL4575; Lopac-T-2265; N,N,N-Triethylethanaminium; NEt4(+); SCHEMBL16267; TETRAETHYLAMMONIUM ION; Tetraethylammonium; Tetraetilammonio; Tetraetilammonio [Italian]; Tetramon; Tetrylammonium; UNII-5AV7G7EIEE; [14C]-TEA; [14C]TEA; tetraethyl ammonium; tetraethylamine; tetraethylazanium
Drug Type
Small molecular drug
Indication Hyperlipidaemia [ICD11: 5C8Z] Phase 2 [1]
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=5413"></iframe>
3D MOL 2D MOL
Formula
C8H20N+
Canonical SMILES
CC[N+](CC)(CC)CC
InChI
InChI=1S/C8H20N/c1-5-9(6-2,7-3)8-4/h5-8H2,1-4H3/q+1
InChIKey
CBXCPBUEXACCNR-UHFFFAOYSA-N
CAS Number
CAS 66-40-0
Pharmaceutical Properties Molecular Weight 130.255 Topological Polar Surface Area 0
Heavy Atom Count 9 Rotatable Bond Count 4
Hydrogen Bond Donor Count 0 Hydrogen Bond Acceptor Count 0
PubChem CID
5413
PubChem SID
103168691 , 104037965 , 104309173 , 106812165 , 11111868 , 124750303 , 124881591 , 125659879 , 126677961 , 126678584 , 127299839 , 127299840 , 127299841 , 127299842 , 127299843 , 127299844 , 127299845 , 127299846 , 127299847 , 127299848 , 127299849 , 127299850 , 127299851 , 127299852 , 127299853 , 127602502 , 127838406 , 1434686 , 15297244 , 24263038 , 26697167 , 29224465 , 37356638 , 49868992 , 50111261 , 53790517 , 560558 , 561143 , 5617425 , 57322763 , 6903206 , 76453784 , 7887259 , 7889355 , 8002309 , 8153330 , 823293 , 823821 , 90340838 , 9715
ChEBI ID
CHEBI:44296
TTD Drug ID
D06PZZ
DT(s) Transporting This Drug MATE1 Transporter Info Multidrug and toxin extrusion protein 1 Substrate [2]
MATE2 Transporter Info Multidrug and toxin extrusion protein 2 Substrate [3]
OCT1 Transporter Info Organic cation transporter 1 Substrate [4]
OCT2 Transporter Info Organic cation transporter 2 Substrate [5]
OCTN1 Transporter Info Organic cation/carnitine transporter 1 Substrate [6]
Drug-Transporter Activity Data
Drug-Transporter Activity Data MATE1 Transporter Info Km = 220 microM Human embryonic kidney cells (HEK293)-MATE1 [2]
MATE1 Transporter Info Km = 380 microM Human embryonic kidney cells (HEK293)-MATE1 [7]
MATE2 Transporter Info Km = 760 microM Human embryonic kidney cells (HEK293)-MATE2K [3]
MATE2 Transporter Info Km = 830 microM Human embryonic kidney cells (HEK293)-MATE2K [8]
OCT1 Transporter Info Km = 229 microM Human cervical cancer cell line (Hela)-OCT1 [9]
OCT1 Transporter Info Km = 566 microM Proximal tubule (S2) cells-OCT1 [4]
OCT2 Transporter Info Km = 63 microM Human embryonic kidney cells (HEK293)-OCT2 [10]
OCT2 Transporter Info Km = 431 microM Human embryonic kidney cells (HEK293)-OCT2 [10]
OCT2 Transporter Info Km = 33.8 microM Oocytes-OCT2 [5]
OCT2 Transporter Info Km = 31 microM Oocytes-OCT2 [11]
OCT2 Transporter Info Km = 76 microM Oocytes-OCT2 [11]
OCTN1 Transporter Info Km = 436 microM Human embryonic kidney cells (HEK293)-OCTN1 [12]
OCTN1 Transporter Info Km = 1800 microM Human embryonic kidney cells (HEK293)-OCTN1 [6]
OCTN1 Transporter Info Km = 195 microM Oocytes-OCTN1 [12]
References
1 ClinicalTrials.gov (NCT00166166) Endothelial Hyperpolarization in Humans
2 A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):17923-8.
3 Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
4 Involvement of human organic cation transporter 1 in the hepatic uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel, small molecule survivin suppressant. Drug Metab Dispos. 2009 Sep;37(9):1856-63.
5 Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes. Biochim Biophys Acta. 1999 Mar 4;1417(2):224-31.
6 Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4). Pharmacogenet Genomics. 2007 Sep;17(9):773-82.
7 The role of microRNA in the delayed negative feedback regulation of gene expression. Biochem Biophys Res Commun. 2007 Jul 6;358(3):722-6.
8 Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol. 2006 Aug;17(8):2127-35.
9 Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61.
10 cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol. 2002 Jul;13(7):1703-10.
11 Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81.
12 Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.